Cell-based therapy for viral diseases
AssigneeOttawa Hospital Research Institute
InventorsShirley H.J. MEI, Luciana DE SOUZA MOREIRA, Yuan TAN, Yan WANG
Life of this patent
Estimating the term…
Abstract
The present application relates to the prevention or treatment of symptoms and diseases caused by viral infections, such as acute respiratory distress syndrome (ARDS), sepsis or septic shock associated with SARS-CoV-2 and influenza virus infections. The treatment is based on the use of mesenchymal stem cells (MSCs) genetically engineered to overexpress suitable polypeptides such as angiopoeitin-1 (ANGPT1) and IFN-induced transmembrane (IFITM). The MSC-based therapy may be administered to the lung of the patient by injection into the blood system.
Claims30
A mesenchymal stem cell (MSC) that is genetically modified to overexpress an angiopoeitin-1 (ANGPT1) polypeptide and an IFN-induced transmembrane (IFITM) polypeptide.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
23-31. (canceled)
(canceled)
38-44. (canceled)
Dependencies are inferred from the claim text.